Antibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunocytochemistry [1]
- Immunohistochemistry [1]
- Other assay [1]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-38077 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- Anti-Phospho-TrkB (Tyr705) Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Synthetic peptide
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µg
- Concentration
- 1 mg/mL
- Storage
- -20°C
Submitted references Discovery of a rare GKAP1-NTRK2 fusion in a pediatric low-grade glioma, leading to targeted treatment with TRK-inhibitor larotrectinib.
Deland L, Keane S, Olsson Bontell T, Sjögren H, Fagman H, Øra I, De La Cuesta E, Tisell M, Nilsson JA, Ejeskär K, Sabel M, Abel F
Cancer biology & therapy 2021 Mar 4;22(3):184-195
Cancer biology & therapy 2021 Mar 4;22(3):184-195
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of Phospho-TrkB pTyr705 in extracts from mouse kidney cells using a Phospho-TrkB pTyr705 polyclonal antibody (Product # PA5-38077).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunofluorescent analysis of Phospho-TrkB pTyr705 in HUVEC cells using a Phospho-TrkB pTyr705 polyclonal antibody (Product # PA5-38077).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemical analysis of Phospho-TrkB pTyr705 in paraffin-embedded human brain tissue using a Phospho-TrkB pTyr705 polyclonal antibody (Product # PA5-38077).
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 5. Functional analysis with Western blot and IHC . (a) Western Blot imaging [I] of HEK293 transiently transfected constructs; empty vector (pCMV6-Myc-DDK; Vector), wild type (pCMV6- NTRK2 -Myc-DDK; NTRK2 WT ) and fusion gene (pCMV6- GKAP1-NTRK2 -Myc-DDK; GKAP1-NTRK2), probed with antibodies against DDK (TRKB-DDK at 120 kDa, and GKAP1-TRKB-DDK at 60-75 kDa), phosphorylated TRKB-Tyr705 (pTRKB; 120 kDa and 60-75 kDa), phosphorylated AKT1/2/3-Ser473/Ser474/Ser472 (pAKT; 52 kDa), total AKT (AKT; 52 kDa), phosphorylated ERK1/2-Thr202/Tyr204 (pERK; 44/42 kDa), total ERK1/2 (ERK; 44/42 kDa), phosphorylated ribosomal protein S6-Ser235/236 (pS6; 32 kDa), S6 ribosomal protein (S6; 32 kDa), and GAPDH (37 kDa). Blot shows representative band(s) from one out of four independent experiments. Scatter plot [II] show pERK/ERK, pAKT/AKT, and pS6/S6 protein quantity from four experiments calculated as fold change (FC) compared to the mean of NTRK2 WT (empty vector = gray, wild type NTRK2 WT = black, GKAP1-NTRK2 = red). Significance was determined using an Ordinary one-way ANOVA followed by Dunnett''s multiple comparisons test. *p < .05, **p < .01, ***p < .001, ns = not significant. (b) Immunohistochemistry (IHC) of FFPE sections from brain tissue with pERK and pAKT antibody. Brain tumor tissue from the GKAP1-NTRK2 fusion-positive case (left panel) show strong immunopositivity for pERK and pAKT in tumor cells, as compared to non-neoplastic brain parenchyma showing low or negative staining